Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

Pierpaolo Trimboli1*, Marco Castellana2†, Camilla Virili3, Francesco Giorgino2 and Luca Giovanella1

1Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, 2Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy, 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

Background: Vandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as end-points.

Methods: The terms “medullary thyroid” and “protein kinase inhibitor” (then including all TKIs) were searched in PubMed, ClinicalTrials.gov, and CENTRAL. Only original studies reporting the use of Vandetanib as single agent in MTC were included. The last search was performed on October 31, 2017 and registered in PROSPERO on December 12, 2017 (n = CRD42017081537).

Results: The search revealed 487 articles, and, after removing duplicates, reading title and abstract, and screening the eligible papers, 10 studied were finally included. Two papers were randomized controlled trials and eight were observational longitudinal studies. No data were available for overall survival. No heterogeneity nor publication bias were recorded in the pooled rate of complete response (0.7%) and stable disease (47%). Mild to moderate heterogeneity were recorded in the pooled rate of other end-points. Data of the studies did not allow to perform a meta-analysis of time-to-event outcomes.

Conclusion: Vandetanib should be considered as a promising treatment in advanced MTC. However, data based on RECIST endpoints do not currently provide high-level evidence on its efficacy.

Keywords: medullary thyroid carcinoma, tyrosine kinase inhibitors, vandetanib, RECIST, systematic review, meta-analysis
INTRODUCTION

Rationale
Medullary thyroid carcinoma (MTC) is a thyroid tumor which can occur as hereditary (20% of cases), due to an activating germline mutation of the REarranged during Transfection (RET) protooncogene, or sporadic (80%), with a somatic RET mutation (1). While the majority of these carcinomas involves only the thyroid gland and reaches the complete cure following total thyroidectomy, a not negligible rate manifests as locally advanced and/or with distant metastases. The latter patients have a poor prognosis and need alternative treatments other than surgery. Generally, the 10-year overall survival (OS) of patients affected by MTC is 95% in patients with local disease, while this rate decreases to 75% in those with regional invasion and 40% in the presence of distant metastases (2).

Objectives
Cytotoxic chemotherapy and external beam radiation therapy are poorly effective for metastatic MTC. For this reason, current guidelines support the use of tyrosine kinase inhibitors (TKIs) as first-line therapy in patients with significant tumor burden and symptomatic or progressive metastatic disease according to RECIST criteria (1). The pathophysiology of this type of tumor and the therapeutic approaches have been studied also by the use of animal models of MTC (3). Vandetanib is the most largely used TKI in advanced MTC, targeting the RET oncogene, the vascular endothelial growth factor receptor, and the epidermal growth factor receptor (4). Following Phase I and II trials, in 2006, the Phase III ZETA randomized clinical trial (RCT) started, based on their results, Vandetanib was eventually approved by the Food and Drug Administration (FDA) for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced or metastatic disease in 2011 (5). Notably, TKIs are frequently associated with severe side effects, and this could be a significant limitation for their chronic use. Furthermore, the discontinuation of a TKI treatment may represent a boost for rapid increase of tumor growth and disease progression (6–8). Thus, whether to treat or not a patient with advanced MTC with TKI may be a difficult decision, and a patient-tailored approach is recommended. MTC is a rare tumor, and this limits our knowledge on the efficacy of TKI in these cancers due to the inherent difficulty in collecting adequate samples for statistical analysis.

Research Question
Here, we have conducted a systematic review on the efficacy of Vandetanib in the treatment of locally advanced and/or metastatic MTC, attempting to perform a meta-analysis with the adoption of standardized RECIST criteria as endpoints (9, 10).

METHODS

Study Design
The study design included studies investigating the efficacy of Vandetanib in MTC patients in terms of RECIST criteria. The present systematic review was registered on December 12, 2017 in PROSPERO (n = CRD42017081537) and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PRISMA checklist can be found in Table S1 in Supplementary Material.

Participants, Interventions, and Comparators
Participants were MTC patients treated with Vandetanib due to advanced disease. There was no comparator.

Search Strategy
To retrieve the best of published literature on the efficacy of Vandetanib in MTC, a four-step search strategy was planned. First, we identified keywords and MeSH terms in PubMed. Second, the terms “medullary thyroid” and “protein kinase inhibitor” (then including all TKIs) were searched in PubMed, ClinicalTrials.gov, and CENTRAL. Third, according to our aim, original studies reporting on the use of Vandetanib as a single agent in patients with locally advanced or metastatic MTC were included for the present analysis. Fourth, references of included studies were searched for additional papers on the same topic. The last search was performed on October 31, 2017. No language restrictions were adopted. Articles with unclear data, case reports, and series with overlapping results were excluded. Two investigators (Marco Castellana and Pierpaolo Trimboli) independently searched papers, screened titles, and abstracts of the retrieved articles, reviewed the full-texts, and selected articles for their final inclusion.

Data Sources, Studies Sections, and Data Extraction
The same two investigators (Marco Castellana and Pierpaolo Trimboli) extracted data independently and in duplicate and in a piloted form. The following data were reported: 1. general information on the study (first author or principal investigator, year of publication, study name, study type and phase, study funding, drug in active treatment and comparator arms, duration of treatment, listed location countries, number and characteristics of patients, such as age, gender, hereditary/sporadic MTC, their previous treatments); 2. endpoints according to RECIST, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), OS, time to response (TTR), duration of response (DOR), and PD as reason for discontinuation. Discrepancies were solved by a mutual consensus among all authors.

Data Analysis
For CR, PR, SD, PD, ORR, DCR, and PD as reason for discontinuation, a proportion meta-analysis was performed; the number of patients with a specific endpoint was extracted from the paper or calculated from the frequency reported in the text. In addition, data on SD at 6, 12, 24, and 36 months, respectively, were searched. For time-to-event outcomes (OS, PFS, TTR, and DOR), a log-rank analysis was attempted. For statistical pooling of the data, the fixed method was used. Pooled data are presented...
with 95% confidence intervals (95% CI) and displayed using a Forest plot, when possible. I² index was used to quantify the heterogeneity among the studies, a significant heterogeneity being defined as an I² value >50%. Egger’s test was also carried out to evaluate the presence of significant publication bias, and a p value <0.05 identified the presence of bias. Statistical analyses were performed using the StatsDirect statistical software version (StatsDirect Ltd., Altrincham, UK).

RESULTS

Study Selection and Characteristics
The search revealed 487 potentially relevant articles. After duplicates removal, 478 were initially selected, and by reading their title and abstract 450 studies were excluded. The full-text of the remaining 28 papers was obtained and evaluated; 18 articles were excluded because of several reasons (i.e., the patients received a TKI other than Vandetanib, Vandetanib was associated with a proteasome inhibitor in the active treatment arm, or no data useful for the meta-analysis were reported). Finally, 10 studies were included in the present systematic review (11–20) (Figure 1).

Synthesized Analysis
The characteristics of the included articles are summarized in Table 1. The studies were published between 2010 and 2017, and reported cohorts of 14–331 MTC patients. Two studies were RCTs, eight were observational longitudinal studies (OLSs); five studies were Phase II OLSs, single-country and single-arm. Five studies were sponsored by industry. Participants were outpatients diagnosed with histologically confirmed, unresectable, locally advanced, or metastatic MTC. Three studies included children and adolescents. A total of 496 patients were treated with Vandetanib in these 10 studies; 100 patients were given placebo in only 1 RCT. One RCT compared the effects of two doses of Vandetanib, i.e., 150 and 300 mg/day. The mean age was 51.2 ± 6.8 years, 56.1% of the patients were male, 24.8% were hereditary MTC, 95.5%
had distant metastases. The median duration of treatment ranged from 8.7 to 39.2 months. Among Vandetanib-treated patients, the median PFS ranged from 7 to 30.5 months (finding from five studies), TTR from 4.3 to 18.6 months (three studies), and DOR from 10.2 to 22.2 months (three studies). Among placebo-treated, a PFS of 19.3 and a DOR of 16.3 months were reported [in one study (13)].

Data of RECIST endpoints available for the meta-analyses are detailed in Table 2. Remarkably, no data were available on OS; among other endpoints, CR, PR, SD, PD, ORR, and DCR were reported in all included studies, while PD as reason for discontinuation in six of them. No heterogeneity nor publication bias were recorded in the pooled rate of CR (0.7%) and SD (47%) (Figures 2 and 3). Data on the rate of SD during the study (i.e., at 6, 12, or 24 months) were reported in few studies, and thus we were not able to perform a meta-analysis on this endpoint. No publication bias and mild-to-moderate heterogeneity were recorded in the pooled rate of the other end-points (Table 3). Data on the included studies did not allow us to perform a meta-analysis on time-to-event outcomes (PFS, TTR, and DOR) because only one study included a placebo arm (13).

### DISCUSSION

#### Summary of Findings

The aim of the current review was to identify the best available evidence on the efficacy of Vandetanib in treating locally advanced or metastatic MTC. Indeed, Vandetanib is currently the most largely used TKI for advanced MTC. To the best of our knowledge, this is the first systematic review and meta-analysis on this topic focusing on the RECIST criteria as benchmark.

---

**TABLE 2** Data available in the included studies and extracted from the meta-analysis.

| Reference               | PFS | OS | CR  | PR  | SD  | PD  | ORR | DCR | TTR | DOR | PD as reason for discontinuation |
|-------------------------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|---------------------------------|
| Robinson et al. (11)    | Yes | No | Yes | Yes | Yes | Yes | Yes | No  | No  | No  | Yes                            |
| Wells et al. (12)       | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes                            |
| Wells et al. (13)       | Yes | No | Yes | Yes | Yes | Yes | Yes | No  | No  | Yes | Yes                            |
| Fox et al. (14)         | No  | No | Yes | Yes | Yes | Yes | Yes | Yes | No  | No  | Yes                            |
| Chougnet et al. (15)    | Yes | No | Yes | Yes | Yes | Yes | Yes | No  | No  | No  | Yes                            |
| Akshintala et al. (16)  | No  | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No  | No                             |
| No author listed, 2016  | No  | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No  | No                             |
| Tiedje et al. (18)      | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No                             |
| Uchino et al. (19)      | No  | No | Yes | Yes | Yes | Yes | Yes | No  | No  | No  | Yes                            |
| Werner et al. (20)      | No  | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No  | No                             |

CR, complete response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TTR, time to response.

---

**FIGURE 2** Forest plot of data on complete response (fixed effect).
TABLE 3 | Results of meta-analysis of RECIST endpoints.

| Endpoint                      | Pooled rate [95% confidence intervals (95% CI)] | I² index (95% CI) | Egger's test (95% CI) | p     |
|-------------------------------|-----------------------------------------------|------------------|---------------------|-------|
| Complete response             | 0.07% (0.007–0.2)                              | 0% (0–53)        | 0.14 (–0.15 to 0.44) | 0.296 |
| Stable disease                | 47% (42–51)                                   | 45% (0–72)       | 0.47 (–1.69 to 2.63) | 0.628 |
| Objective response rate       | 35% (31–40)                                   | 71% (33–83)      | −0.51 (–3.52 to 2.48) | 0.701 |
| Disease control rate          | 83% (80–86)                                   | 69% (27–82)      | −0.98 (–3.66 to 1.70) | 0.422 |
| Partial response              | 35% (31–40)                                   | 73% (40–84)      | 0.33 (0.24–0.43)     | 0.755 |
| Progressive disease (PD)      | 14% (11–17)                                   | 61% (1–79)       | 0.59 (–1.84 to 3.01) | 0.593 |
| PD as reason for discontinuation of Vandetanib | 30% (26–35)                               | 65% (0–83)       | −0.7 (–4.91 to 3.50) | 0.685 |

I² index quantified the heterogeneity among the studies, and a value >50% indicated significant heterogeneity; Egger’s test evaluated the publication bias, identified by a p value <0.05.

Notably, most of the retrieved papers (both original reports and reviews) identified by our search strategy focused on the side-effects, rather than on the efficacy of TKI, and only two RCTs and eight OLSs were eligible for inclusion in our analysis. As a major result, no analysis could be performed for OS because this finding was not reported in any of these 10 articles. The pooled CR and SD were the most statistically relevant results; less than 1 in 100 MTC patients had a CR to Vandetanib and about a half (47%) showed a SD at the end of the study. The other dichotomous endpoints presented statistical limitations (i.e., significant heterogeneity), while time-to-event outcomes could not be meta-analyzed due to the design of the studies.

As mentioned above, OS of MTC patients is significantly reduced in the presence of metastases (2). Besides the local effects caused by metastases in the liver, bone, lung, and mediastinal region, patients with advanced MTC may suffer from diarrhea (due to hypercalcitoninemia) or from Cushing’s syndrome due to ectopic ACTH or CRH secretion (1). Remarkably, TKI treatment might cause side effects, diminishing the patient’s quality of life. The more common adverse effects are gastrointestinal (diarrhea, nausea, and decreased appetite), cardiovascular (hypertension, QTc prolongation), dermatological (acne, skin rash), and general symptoms such as fatigue (6). Adverse events may occur in mild or severe forms; dose reduction may lead to improvement of side effects in mild cases while in severe forms Vandetanib should be interrupted until symptoms improve (7). Since metastatic MTC is incurable, it is necessary to consider that usually TKI treatment must be continued chronically, and the above side effects may impact on the patients’ quality of life (6). Furthermore, the long-term effects of the chronic use of Vandetanib are not known (1). Therefore, once metastases have appeared and/or there is a local cervical invasion, the clinician must carefully identify the best treatment considering the possibility to slow tumor progression but also the risk of side effects in the context of the best quality of life possible (8). On this ground, recent studies are proposing alternative treatments that could lead to a more individually tailored treatment (21).

A meta-analysis on TKIs for advanced metastatic thyroid cancer, including several cancer types, has been recently published.
Six RCTs were included, one of which herein included also (13). Higher PFS was reported among Vandetanib- and Cabozantinib-treated patients with respect to controls (HR = 0.36; 95% CI, 0.22–0.58) (22). However, since these authors included in their meta-analysis studies with different therapies, their results could not be compared with those in our meta-analysis.

Limitations
Some potential limitations of our meta-analysis should be addressed. According to our search strategy, we could find both RCTs and OLSs. The study design of these papers was evidently highly different (duration of the study, dose of Vandetanib used) and the series included different patient types (i.e., adults/adolescents, patients previously treated with systemic therapy or not, hereditary/sporadic MTC). Also, some studies adopted RECIST 1.0 (9) to evaluate the response to therapy, while others used the version 1.1 (10). All of these discrepancies might affect the herein reported pooled results. On February 2018, then after our literature search, an update of NCT00514046 was published by Kraft et al. (23); endpoints according to RECIST did not differ from the one reported by Akshintala et al. (16).

Conclusion
This study demonstrates that a negligible rate of patients with advanced MTC treated by Vandetanib has a CR at the end of the study and less than a half has SD. Vandetanib, the most largely used therapy in advanced MTC, should be considered as a promising treatment in these patients. However, data on RECIST endpoints to be analyzed are limited, and the overall evidence on the efficacy of Vandetanib in advanced MTC should thus be considered as low at present. Furthermore, RCTs are needed to obtain more robust information, especially in terms of OS.

ETICS STATEMENT
This article does not contain any studies with human participants or animals performed by any of the authors.

AUTHOR’S NOTE
This systematic review was registered in PROSPERO (n = CRD42 017081537).

AUTHOR CONTRIBUTIONS
PT, MC, and LG conceived and designed the study. PT, MC, and CV performed the literature search; PT analyzed the data; FG and LG critically reviewed the results. All the authors contributed to write the manuscript.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fendo.2018.00224/full#supplementary-material.

REFERENCES
1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid* (2015) 25:567–610. doi:10.1089/thy.2014.0335
2. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. *Cancer* (2006) 107:2134–42. doi:10.1002/cncr.22244
3. Vitale G, Gaudenzi G, Circelli L, Manzoni MF, Bassi A, Fioritti N, et al. Animal models of medullary thyroid cancer: state of the art and view to the future. *Endocr Relat Cancer* (2017) 24:R1–12. doi:10.1530/ERC-16-0399
4. Valerio I, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, et al. Targeted therapy in thyroid cancer: state of the art. *Clin Oncol (R Coll Radiol)* (2017) 29:316–24. doi:10.1016/j.clon.2017.02.009
5. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/ida-vandetanib (Accessed: October 31, 2017).
6. Resteghini C, Cavaliere S, Galliati D, Granata R, Alfieri S, Bergamini C, et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. *Best Pract Res Clin Endocrinol Metab* (2017) 31:349–61. doi:10.1016/j.beem.2017.04.012
7.Fallahii P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, et al. Selective use of vandetanib in the treatment of thyroid cancer. *Drug Des Devel Ther* (2015) 9:3459–70. doi:10.2147/DDDT.S72495
8. Maciel LMZ, Magalhães PKR. Medullary thyroid carcinoma – adverse events during systemic treatment: risk-benefit ratio. *Arch Endocrinol Metab* (2017) 61:398–402. doi:10.1590/2359-3997000000267
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). *J Natl Cancer Inst* (2000) 92:205–16. doi:10.1093/jnci/92.3.205
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* (2009) 45:228–47. doi:10.1016/j.ejca.2008.10.026
11. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R, Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Endocrinol Metab* (2010) 95:2664–71. doi:10.1210/jc.2009-2461
12. Wells SA Jr, Gosnell JE, Vandetanib (100 mg) for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Oncol* (2010) 28:767–72. doi:10.1200/JCO.2009.23.6604
13. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* (2012) 30:134–41. doi:10.1200/JCO.2011.35.5040
14. Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. *Clin Cancer Res* (2013) 19:4239–48. doi:10.1158/1078-0432.CCR-13-0071
15. Chougnet CN, Boret G, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. *Thyroid* (2015) 25:386–91. doi:10.1089/thy.2014.0361
16. Akshintala S, Dombi E, Glastonbury CD, Fox E, Lodish M, Whitcomb PO, et al. Response and Resistance to the Receptor Tyrosine Kinase Inhibitor (TKI) Vandetanib in Pediatric Patients With Medullary Thyroid Carcinoma (MTC). *Pediatric Blood and Cancer* (2017) 64:501–6. doi:10.1002/pbc.26250. Conference: 2017 American Society of Pediatric Hematology/Oncology, ASHPO 2017. Conference start: 20150506. Conference end: 20150509.
17. Available from: https://clinicaltrialresults.com/ctz/show/NCT01496313?term=NCT01496313&rank=1 (Accessed: October 31, 2017).
18. Tiedje V, Ting S, Walter RF, Herold T, Worm K, Badziong J, et al. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. *Eur J Endocrinol* (2016) 175:173–80. doi:10.1530/EJE-16-0252

19. Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horisuchi K, Tsuji A, et al. Safety and tolerability of vandetanib in Japanese patients with medullary thyroid cancer: a phase I/II open-label study. *Endocr Pract* (2017) 23:149–56. doi:10.4158/EP161259.OR

20. Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märdl B, et al. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. *J Nucl Med* (2017). doi:10.2967/jnumed.117.199778

21. Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, et al. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. *Endocrine* (2018). doi:10.1007/s12020-018-1583-7

22. Liu JW, Chen C, Loh EW, Chu CC, Wang MY, Ouyang HJ, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. *Curr Med Res Opin* (2018) 34(5):795–803. doi:10.1080/03007995.2017.1368466

23. Kraft IL, Akohintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, et al. Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. *Clin Cancer Res* (2018) 24:753–65. doi:10.1158/1078-0432.CCR-17-2101

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Trimboli, Castellana, Virili, Giorgino and Giovanella. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.